サンプル依頼リスト カート
  • English
  • Korean
表紙：リウマチ性多発筋痛治療の世界市場：2023年～2030年
市場調査レポート
商品コード
1382516

リウマチ性多発筋痛治療の世界市場：2023年～2030年

Global Polymyalgia Rheumatica Treatment Market - 2023-2030

出版日
ページ情報
英文 186 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=159.08円
リウマチ性多発筋痛治療の世界市場：2023年～2030年
出版日: 2023年11月17日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

概要

リウマチ性多発筋痛症と呼ばれる炎症性疾患は、耐えがたい痛みとこわばりを特徴とし、両側の肩と腕の近位部を侵します。PMRを治療せずに放置すると、生活の質が著しく低下します。

炎症を抑え、症状を治療するために、PMR治療の一環として副腎皮質ステロイドが頻繁に使用されます。副腎皮質ステロイドは悪影響を及ぼす可能性があるため、最小の有効量を最短時間で使用することが目的です。長期にわたるコルチコステロイド療法の必要性を減らすために、メトトレキサートなどの疾患修飾性抗リウマチ薬（DMARDs）が投与されることもあります。

PMR治療の重要な動機のひとつは高齢化です。画像診断や血液検査などの診断方法が改善された結果、PMRの診断がより早く、より正確に行われるようになったことが、治療の必要性の引き金となったのかもしれません。PMRの根本原因を継続的に調査し、将来的な標的治療を行うことで、副作用の少ない、より効率的な治療薬が生まれる可能性があります。

市場力学：促進要因

研究活動の活発化

原因不明の持続性炎症性疾患であるリウマチ性多発筋痛症（PMR）は、50歳以上の成人にのみ発症します。女性の約2.4％、男性の約1.7％がPMRに罹患しており、高齢者に最も多い炎症性リウマチ性疾患の一つであり、その発症率は関節リウマチに次いで2番目です。肩甲骨や骨盤帯の不快感、朝のこわばり、急性期反応物質の上昇がPMRの特徴であり、グルココルチコイド（GC）療法に反応します。

2023年2月、FDAは、副腎皮質ステロイドが十分に奏効しない、または副腎皮質ステロイドの漸減に耐えられない炎症性リウマチ性疾患であるリウマチ性多発筋痛症（PMR）の成人患者の治療薬として、ケブザラ（サリルマブ）を承認しました。このニュースはリジェネロン社とサノフィ社によって共有されました。リジェネロン社およびサノフィ社は、ケブザラを処方された米国人に対し、投薬および必要なサポートを提供することに全力を尽くしています。

2022年9月現在、プレドニゾン療法にもかかわらず、オシリズマブ（アクテムラ）は活動性のリウマチ性多発筋痛症患者に有意な効果をもたらすようです。Journal of the American Medical Associationによると、リウマチ性多発筋痛症の患者さんは肩や骨盤が痛く、柔軟性がありません。リウマチ性多発筋痛症に罹患するのは男女ともに2％程度であるが、50歳から80歳の間に発症することが多いです。

副腎皮質ステロイドへの依存

副腎皮質ステロイド（主にプレドニン）はPMR治療の主役です。副作用のために副腎皮質ステロイドの長期使用は制限されます。ステロイドに関連した合併症、標的治療薬の不足、メトトレキサートのような疾患修飾性抗リウマチ薬（DMARDs）の副作用などの他の要因が、コルチコステロイド依存性を軽減するために用いられています。しかし、DMARDsには肝毒性や胃腸障害などの副作用があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 研究活動の活発化
    • 抑制要因
      • 副腎皮質ステロイドへの依存
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • SWOT分析
  • 特許分析
  • DMIオピニオン

第6章 COVID-19分析

第7章 薬剤クラス別

  • コルチコステロイド
  • 疾患修飾性抗リウマチ薬（DMARDS）
  • 非ステロイド性抗炎症薬（NSAIDS）
  • その他

第8章 投与経路別

  • 経口
  • 非経口
  • その他

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • F. Hoffmann-La Roche Ltd.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Sanofi
  • Novartis AG
  • Regeneron Pharmaceuticals
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • AstraZeneca
  • Merck & Co., Inc.
  • PuraCap Pharmaceutical LLC

第13章 付録

目次
Product Code: PH7431

Overview

An inflammatory condition called polymyalgia rheumatica is characterized by excruciating pain and stiffness that affects the shoulders and proximal parts of the arms on both sides. The quality of life is significantly reduced when PMR is left untreated.

Corticosteroids are frequently used as part of PMR treatment to reduce inflammation and treat symptoms. The aim is to utilize the lowest effective dose for the shortest amount of time because corticosteroids may have negative effects. To lessen the requirement for long-term corticosteroid therapy, disease-modifying antirheumatic medications (DMARDs) such as methotrexate may occasionally be administered.

One of the key motivators for PMR treatment is the aging population. The majority of PMR illnesses mostly affect people over 50, and as the population ages, more instances are anticipated.The need for treatment may be triggered by an earlier and more accurate diagnosis of PMR as a result of improved diagnostic methods, including imaging and blood testing. Continuous investigation into the root causes of PMR and prospective targeted therapy could result in the creation of more efficient medications with fewer side effects.

Market Dynamics: Drivers

The Increasing Research Activities

A persistent inflammatory condition with an unclear cause, polymyalgia rheumatica (PMR) only affects adults over the age of 50. About 2.4% of women and 1.7% of men are affected by PMR, which has been one of the most prevalent inflammatory rheumatic diseases in older individuals and whose incidence is only second to rheumatoid arthritis. Scapular and pelvic girdle discomfort, morning stiffness, and raised acute phase reactants are the hallmarks of PMR, which responds to glucocorticoid (GC) therapy.

In February 2023, the FDA approved Kevzara (sarilumab) for the treatment of adult patients with polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, who have not responded adequately to corticosteroids or who are unable to tolerate corticosteroid tapering. This news was shared by Regeneron Pharmaceuticals, Inc. and Sanofi. Both Regeneron and Sanofi are dedicated to assisting Americans who have been prescribed Kevzara in getting the medication and any necessary support.

As of September 2022, in spite of prednisone therapy, ocilizumab (Actemra) appears to produce significant effects in patients with active polymyalgia rheumatica. According to Journal of the American Medical Association, the shoulder and pelvic girdles are painful and inflexible for those who have polymyalgia rheumatica. Although only approximately 2% of men and women may encounter the ailment, the condition often manifests between the ages of 50 and 80.

Dependency on Corticosteroids

Corticosteroids, primarily prednisone, are the mainstay of PMR treatment. The side effects can limit the long-term use of corticosteroids. Other factors including steroid-related complications, lack of targeted therapies, side effects of disease-modifying antirheumatic drugs (DMARDs) like methotrexate are used to reduce corticosteroid dependence. However, DMARDs can have their own side effects, including liver toxicity and gastrointestinal issues.

Segment Analysis

The global polymyalgia rheumatica treatment market is segmented based on drug class, route of administration, distribution channel and region.

The corticosteroids segment accounted for approximately 43.3% of the market share

An effective way to treat PMR is by giving a corticosteroid like prednisone, which reduces discomfort and swelling. With a progressive dose increase for the first few months, the patient must continue the medication for around a year.

The main treatment up until now has been corticosteroids, but many patients do not respond well to them or cannot be weaned off them, putting them in danger of problems from long-term steroid medication. With the FDA's approval of Kevzara for polymyalgia rheumatica, patients now have a medication that can aid with the debilitating symptoms of this condition and long-term steroid reliance.

In the United Kingdom, depending on symptom remission and inflammatory markers like C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), such as those measured by Arvind Nune, MRCP, consultant rheumatologist at Southport and Ormskirk Hospital NHS Trust, the standard treatment is 15 milligrams of prednisone for up to 3-4 weeks.

Geographical Penetration

North America accounted for approximately 41% of the market share

North America has been a dominant force in the global polymyalgia rheumatica treatment market. The majority of PMR cases afflict those over 50, and as the population ages, the prevalence of cases is anticipated to rise, increasing the need for PMR treatments. In some largely white populations, PMR has been found to be the second most frequent inflammatory autoimmune rheumatic disease after rheumatoid arthritis. The average yearly incidence of polymyalgia rheumatica (PMR) in those aged 50 and older in the United States is 52.5 cases per 100,000.

Furthermore, the greatest chance of acquiring PMR or giant cell arteritis, a similar illness, is among Caucasian women over the age of 50. According to estimates, 700 out of every 100,000 Americans over the age of 50 in the general population have PMR. It is quite rare for someone under 50 to acquire PMR.

Low doses of corticosteroid therapy are used to treat PMR. The lowest effective dose of steroids, often prednisone, is prescribed and adjusted by healthcare professionals to be between 15 and 20 mg per day. The stiffness brought on by PMR often goes away in three days.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global polymyalgia rheumatica treatment market. Many people may have postponed or avoided getting medical attention for non-urgent diseases, such as PMR, during the COVID-19 epidemic. When patients eventually sought medical care, it was possible that the symptoms were worse because of the delay in diagnosis and treatment.

During the pandemic, healthcare providers used telemedicine more and more to limit in-person visits and the danger of viral exposure. The management of PMR was impacted by this change in healthcare delivery, which involved clinicians remotely prescribing drugs and offering guidance.

By Drug Class

  • Corticosteroids
  • Disease-Modifying Anti-Rheumatic Drugs (DMARDS)
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

major global players in the market include: F. Hoffmann-La Roche Ltd., Sanofi, Novartis AG, Regeneron Pharmaceuticals, Mylan N.V., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca, Merck & Co., Inc., and PuraCap Pharmaceutical LLC among others.

Key Developments

  • In September 2023, Novartis reported a randomized, parallel-group, double-blind, placebo-controlled, multicenter phase III trial to evaluate the efficacy and safety of secukinumab administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with Polymyalgia Rheumatica (PMR).

Why Purchase the Report?

  • To visualize the global polymyalgia rheumatica treatment market segmentation based on drug class, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of polymyalgia rheumatica treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global polymyalgia rheumatica treatment market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Class
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Research Activities
    • 4.1.2. Restraints
      • 4.1.2.1. Dependency on Corticosteroid
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. SWOT Analysis
  • 5.7. Patent Analysis
  • 5.8. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Corticosteroids*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Disease-Modifying Anti-Rheumatic Drugs (DMARDS)
  • 7.4. Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
  • 7.5. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Parenteral
  • 8.4. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. F. Hoffmann-La Roche Ltd.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Sanofi
  • 12.3. Novartis AG
  • 12.4. Regeneron Pharmaceuticals
  • 12.5. Mylan N.V.
  • 12.6. Teva Pharmaceutical Industries Ltd.
  • 12.7. Pfizer Inc.
  • 12.8. AstraZeneca
  • 12.9. Merck & Co., Inc.
  • 12.10. PuraCap Pharmaceutical LLC

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us